Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Optimization for CART19 Associated CRS
NCT02906371Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Aug 2016
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of tocilizumab in cytokine release syndrome (CRS) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Frequency of Grade 4 Cytokine Release Syndrome at 1 year. Started Aug 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT02906371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906371.